Analyst Price Targets — STVN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 10, 2026 2:10 pm | — | Jefferies | $17.50 | $15.95 | TheFly | Stevanato Group price target lowered to $17.50 from $23 at Jefferies |
| December 1, 2025 9:33 pm | — | Morgan Stanley | $24.00 | $22.58 | TheFly | Stevanato Group assumed with an Equal Weight at Morgan Stanley |
| August 7, 2024 6:36 am | Patrick Donnelly | Citigroup | $28.00 | $19.87 | TheFly | Stevanato Group price target lowered to $28 from $30 at Citi |
| July 15, 2024 8:00 am | Drew Ranieri | Morgan Stanley | $22.00 | $21.71 | TheFly | Stevanato Group price target lowered to $22 from $26 at Morgan Stanley |
| September 26, 2023 3:48 pm | Jacob Johnson | Stephens | $33.00 | $27.07 | Benzinga | When Will Stevanato's Free Cash Flow Turn Positive? This Analyst Has An Answer |
| January 6, 2023 10:34 am | — | Morgan Stanley | $22.00 | $19.85 | Benzinga | Morgan Stanley Maintains Overweight on Stevanato Group, Lowers Price Target to $22 |
| April 25, 2022 9:20 am | — | Wells Fargo | $19.00 | $16.59 | Benzinga | Wells Fargo Maintains Overweight on Stevanato Group, Lowers Price Target to $19 |
Latest News for STVN
Artisan Partners Limited Partnership trimmed its position in shares of Stevanato Group S.p.A. (NYSE: STVN) by 4.4% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,613,242 shares of the company's stock after selling 120,540 shares during
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the fourth quarter and fiscal year 2025 on Wednesday, March 4, 2026, at 6:30 a.m. (ET). Conference call and webcast: The Company…
Stevanato Group (NYSE: STVN - Get Free Report) and Kiora Pharmaceuticals (NASDAQ: KPRX - Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation. Profitability This table compares Stevanato Group and Kiora
Shares of Stevanato Group S.p.A. (NYSE: STVN - Get Free Report) hit a new 52-week low on Friday. The stock traded as low as €15.40 and last traded at €16.02, with a volume of 1057900 shares trading hands. The stock had previously closed at €16.02. Analyst Upgrades and Downgrades STVN has been the topic of
Class A shares of the Alger Small Cap Focus Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Guardant Health, Inc., and Natera, Inc. were among the top contributors to performance. Nebius Group, uniQure N.V., and Stevanato Group were among the top detractors from performance.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for STVN.
Senate Trading
No Senate trades found for STVN.
U.S. House Trading
No House trades found for STVN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.